Cholesterol care | New York
Leqvio is the brand name for inclisiran, an FDA-approved small interfering RNA medicine for certain patients who need additional LDL cholesterol lowering. Under the current U.S. label, a healthcare professional gives it under the skin at the start, again at three months, and then every six months. A Nao Medical visit can assess clinical fit and coordinate next steps, but the location cards on this page do not confirm on-site stock or administration.
Leqvio is FDA approved and has an active U.S. acquisition and distribution pathway. The current prescribing information was revised in February 2026. This page describes evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The current label covers adults with hypercholesterolemia and patients age 12 years and older with heterozygous or homozygous familial hypercholesterolemia as an adjunct to diet and exercise. The medicine lowers LDL cholesterol; the clinician must apply the full label to the individual patient.
The review should establish the type of hypercholesterolemia, current LDL level and goal, age, prior and current lipid-lowering therapy, adherence, pregnancy or lactation considerations, and whether another approach is more appropriate.
The labeled dose is 284 mg by subcutaneous injection, given by a healthcare professional initially, at three months, and every six months after that.
A clinician should plan lipid testing and assess injection-site reactions or other concerns. The current label also addresses dosing in relation to LDL apheresis and use in specific populations.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The review should establish the type of hypercholesterolemia, current LDL level and goal, age, prior and current lipid-lowering therapy, adherence, pregnancy or lactation considerations, and whether another approach is more appropriate.
A clinician should plan lipid testing and assess injection-site reactions or other concerns. The current label also addresses dosing in relation to LDL apheresis and use in specific populations.
HCP administration requires confirmed buy-and-bill or specialty-pharmacy workflow, shipment destination, cold-chain storage, staffing, documentation, and site capability before scheduling.
Leqvio is not a walk-in injection. A complete clinical review, prescription, coverage decision, product acquisition, shipment, storage, and confirmed administration site may all be needed before treatment can occur.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
Bring recent lipid results, a current medication and supplement list, prior reactions, relevant diagnoses, and family history when available.
The clinician reviews the reason for treatment, prior response, safety considerations, adherence barriers, and the role of lifestyle support.
The plan may include repeat or additional testing, a medication change, teaching, prior-authorization work, specialist coordination, or continued monitoring.
The care team confirms how results and symptoms will be reviewed. Product supply or administration is arranged only after operational capability is verified.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Explore broader cardiovascular prevention and cholesterol care at Nao Medical.
Review very high LDL levels and family history before choosing a treatment path.
Clarify symptoms and prior statin trials instead of assuming that every symptom proves intolerance.
Learn when Lp(a), ApoB, and other measurements may add useful context.
Compare a self-injected PCSK9 antibody with a clinician-administered option.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
FDA-approved identity, indications, healthcare-professional administration, dosage, and safety information.
Open official sourceActive U.S. acquisition channels and operational distribution context.
Open official sourceCurrent risk assessment, LDL-lowering treatment, Lp(a), ApoB, and monitoring guidance.
Open official sourcePatient-selection principles and the roles of Lp(a), ApoB, and nonstatin therapies.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371